Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sandostatin LAR dosing schedule comparison in uncontrolled acromegaly
2005-003444-53Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2005
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of octreotide in acromegaly (2 arms), sponsored by Novartis. Started Dec 2005; status: completed.
02
Drugs
octreotide
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2005-003444-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003444-53.